Another strong quarter...shares are dirt cheap right now...buy, buy, buy...get in while you can..."Medivolve delivered another strong quarter of financial results, achieving a 48% increase in revenue growth compared to Q1 in 2021," said David Preiner, CEO of Medivolve. "We're incredibly proud to continue delivering strong financial results for our shareholders while delivering exceptional patient care.”
Cash on hand was $8,327,812 as at March 31, 2022, up 7,309% compared to $112,397 as at December 31, 2021.
Cash provided by operating activities was $8,211,415 in the three months ending March 31, 2022, compared to cash used by operating activities of $4,382,478 in the prior three months ending March 31, 2021.
Revenue was $16,693,947 in the three months ending March 31, 2022, up 48%, compared to $11,248,001 over the prior three months ending March 31, 2021.
Gross profit was $6,409,277 in the three months ending March 31, 2022, up 518%, compared to $1,053,888 over the prior three months ending March 31, 2021.
On May 3, 2022, the Company announced its intention to commence a Normal Course Issuer Bid to buy back its common shares through the facilities of NEO Exchange Inc. and/or other Canadian alternative trading platforms.